Multiplex immunofluorescence IHC
Materials Required
Principle
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species[1][2][3]. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment[2][3][4][5][6].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use FFPE tissue sections, antigen-retrieval/stripping buffer such as citrate buffer pH 6.0 when validated for the panel, blocking reagents, HRP-compatible detection reagents, wash buffer, mounting medium, and DAPI-containing nuclear counterstain; tissue fixation, storage, sectioning, antigen retrieval, antibody stripping, and staining order should be standardized because they affect signal quality and reproducibility[2][4][5][7].
• Use validated primary antibodies for each biomarker, HRP-linked secondary detection, TSA fluorophore reagents with spectrally separable emission profiles, and DAPI; each antibody should first be tested by conventional IHC and singleplex IF before multiplex assembly, and the fluorophore-antibody pairing and marker order should be optimized because biomarker abundance, co-expression, epitope stability, and spectral overlap can affect interpretation[2][3][5][7].
• Use a microtome for FFPE sectioning, staining platform or manual staining setup, microwave/heat device for antigen retrieval and antibody stripping, humidified incubation chamber, fluorescence or multispectral slide scanner, spectral unmixing software, and digital pathology software for segmentation, phenotype classification, density calculation, and spatial analysis[2][3][5][6].
• Use validated primary antibodies for each biomarker, HRP-linked secondary detection, TSA fluorophore reagents with spectrally separable emission profiles, and DAPI; each antibody should first be tested by conventional IHC and singleplex IF before multiplex assembly, and the fluorophore-antibody pairing and marker order should be optimized because biomarker abundance, co-expression, epitope stability, and spectral overlap can affect interpretation[2][3][5][7].
• Use a microtome for FFPE sectioning, staining platform or manual staining setup, microwave/heat device for antigen retrieval and antibody stripping, humidified incubation chamber, fluorescence or multispectral slide scanner, spectral unmixing software, and digital pathology software for segmentation, phenotype classification, density calculation, and spatial analysis[2][3][5][6].
Experimental Procedure
• Cut FFPE tissue sections at 4 µm when following commonly reported mIF workflows, prepare serial sections for singleplex controls and multiplex staining, and include appropriate control tissues such as tonsil or other marker-positive tissues selected for the panel[2][5][6].
• Before multiplex staining, validate each antibody by chromogenic IHC and singleplex IF, then compare the multiplex signal against singleplex or chromogenic reference staining when possible; reported validation workflows used positive controls, negative controls, autofluorescence controls, serial tissue sections, and comparison to conventional IHC[2][5][7].
• Perform deparaffinization and antigen retrieval, then stain one biomarker per cycle using primary antibody, HRP-based secondary detection, TSA fluorophore deposition, and heat-mediated antibody stripping before the next biomarker cycle; repeat the cycle until all markers are stained, then apply DAPI and coverslip[1][2][3][4].
• Use up to seven colors or up to eight markers only after panel validation, because published workflows describe 7-color panels and TSA-based detection of up to eight biomarkers, while repeated heat cycles can alter epitope detection and require marker-order optimization[3][4][5].
• Assign staining order and fluorophore pairing empirically rather than assuming plug-and-play performance; published optimization work found that staining order, Opal-antibody pairing, tissue thickness, multispectral unmixing, and marker-detection order during image analysis influenced image quality and quantitative output[5][7].
• Acquire multiplex images using multispectral microscopy or a validated fluorescence whole-slide system, build spectral libraries or single-stain references for unmixing, subtract tissue autofluorescence when included in the workflow, and segment cells using nuclear and morphological information before assigning marker-positive phenotypes[2][3][5][6].
• Interpret results as marker expression, co-expression-defined cell phenotypes, cell densities, and spatial relationships; examples include CD3+CD8+ cytotoxic T cells, CD3+CD4+ helper T cells, FOXP3+ regulatory T cells, PD-L1+ epithelial tumor cells, and PD-L1+ macrophages[2][3].
• Use batch controls, positive and negative controls, autofluorescence controls, and reproducibility checks; published studies compared multiplex IF to conventional IHC, used control tissues across staining batches, and reported strong correlations between chromogenic IHC and multiplex IF in validated panels[2][5][7].
• Before multiplex staining, validate each antibody by chromogenic IHC and singleplex IF, then compare the multiplex signal against singleplex or chromogenic reference staining when possible; reported validation workflows used positive controls, negative controls, autofluorescence controls, serial tissue sections, and comparison to conventional IHC[2][5][7].
• Perform deparaffinization and antigen retrieval, then stain one biomarker per cycle using primary antibody, HRP-based secondary detection, TSA fluorophore deposition, and heat-mediated antibody stripping before the next biomarker cycle; repeat the cycle until all markers are stained, then apply DAPI and coverslip[1][2][3][4].
• Use up to seven colors or up to eight markers only after panel validation, because published workflows describe 7-color panels and TSA-based detection of up to eight biomarkers, while repeated heat cycles can alter epitope detection and require marker-order optimization[3][4][5].
• Assign staining order and fluorophore pairing empirically rather than assuming plug-and-play performance; published optimization work found that staining order, Opal-antibody pairing, tissue thickness, multispectral unmixing, and marker-detection order during image analysis influenced image quality and quantitative output[5][7].
• Acquire multiplex images using multispectral microscopy or a validated fluorescence whole-slide system, build spectral libraries or single-stain references for unmixing, subtract tissue autofluorescence when included in the workflow, and segment cells using nuclear and morphological information before assigning marker-positive phenotypes[2][3][5][6].
• Interpret results as marker expression, co-expression-defined cell phenotypes, cell densities, and spatial relationships; examples include CD3+CD8+ cytotoxic T cells, CD3+CD4+ helper T cells, FOXP3+ regulatory T cells, PD-L1+ epithelial tumor cells, and PD-L1+ macrophages[2][3].
• Use batch controls, positive and negative controls, autofluorescence controls, and reproducibility checks; published studies compared multiplex IF to conventional IHC, used control tissues across staining batches, and reported strong correlations between chromogenic IHC and multiplex IF in validated panels[2][5][7].
Troubleshooting
Unexpected signal in a channel or apparent false co-localization:
Possible CauseSpectral bleed-through, fluorophore overlap, or inappropriate detection order during image analysis; Literature-supported Solutio- Use single-stain controls for spectral unmixing, revise fluorophore-antibody pairing, and validate marker-detection order against singleplex references[5][7].
Weak or lost staining for later-cycle markers:
Possible CauseRepeated heat-induced retrieval/stripping can affect epitope stability; Literature-supported Solutio- Test candidate markers at different staining-cycle positions and place heat-sensitive or low-expression targets in positions supported by singleplex-to-multiplex validation[4][5][7].
Cross-reactivity between staining cycles:
Possible CauseIncomplete removal of primary or secondary antibodies before the next cycle; Literature-supported Solutio- Use heat-mediated antibody stripping after TSA deposition and confirm absence of carryover with omission or dropout controls before accepting the multiplex panel[1][2][4][7].
Quantitative results differ between batches or tissue sections:
Possible CauseTissue thickness, fixation/storage differences, staining variation, or inconsistent image-analysis parameters; Literature-supported Solutio- Standardize tissue processing and sectioning, include control tissue in each staining batch, and validate multiplex results against singleplex or chromogenic IHC where feasible[2][5][7].
References:
- [1]. Tóth ZE, et al. Simultaneous visualization of multiple antigens with tyramide signal amplification using antibodies from the same species. J Histochem Cytochem. 2007;55(6):545-554. [Content Brief]
- [2]. Parra ER, Uraoka N, Jiang M, et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017;7(1):13380. [Content Brief]
- [3]. Hernandez S, Rojas F, Laberiano C, et al. Multiplex immunofluorescence tyramide signal amplification for immune cell profiling of paraffin-embedded tumor tissues. Front Mol Biosci. 2021;8:667067. [Content Brief]
- [4]. Sun Z, et al. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. PLoS One. 2021;16(2):e0247238. [Content Brief]
- [5]. Viratham Pulsawatdi A, Craig SG, Bingham V, et al. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Mol Oncol. 2020;14(10):2384-2402. [Content Brief]
- [6]. Mori H, Bolen J, Schuetter L, et al. Characterizing the tumor immune microenvironment with tyramide-based multiplex immunofluorescence. J Mammary Gland Biol Neoplasia. 2021;26(2):129-143. [Content Brief]
- [7]. Parra ER, Jiang M, Solis L, et al. Procedural requirements and recommendations for multiplex immunofluorescence tyramide signal amplification assays to support translational oncology studies. Cancers (Basel). 2020;12(2):255. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail